(Q36731130)

15 August 2017

1 reference

title

Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation (English)

1 reference

15 August 2017

1 reference

Eric C Nelson

1

1 reference

15 August 2017

Angelo J Cambio

2

1 reference

15 August 2017

Joy C Yang

3

1 reference

15 August 2017

Primo N Lara

4

1 reference

15 August 2017

Christopher P Evans

5

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

15 August 2017

published in

Nature Reviews Urology

1 reference

15 August 2017

volume

4

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

82-94

1 reference

Angiogenesis-targeted therapies in prostate cancer

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

21 January 2018

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Androgen receptor as a therapeutic target for androgen independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

The development of androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Mechanisms of the development of androgen independence in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Transcriptional regulation by steroid receptor coactivator phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Expression and function of androgen receptor coactivators in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Smart drugs in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Future therapies in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Neuroendocrine cells in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Early castration-induced upregulation of transforming growth factor beta1 and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Integrin signalling and tyrosine phosphorylation: just the FAKs?

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Fibronectin, integrins, and growth control

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Effects of the natural isoflavonoid genistein on growth, signaling pathways and gene expression of matrix macromolecules by breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Bortezomib as a potential treatment for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

NF-kappaB as a therapeutic target in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Molecular insights into prostate cancer progression: the missing link of tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Expression patterns of potential therapeutic targets in prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Neuropeptides bombesin and calcitonin inhibit apoptosis-related elemental changes in prostate carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Regulatory effect of castration on endothelins, their receptors and endothelin‐converting enzyme in rat seminal vesicle

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Targeting apoptosis in prostate cancer: focus on caspases and inhibitors of apoptosis proteins

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

The role of integrin-linked kinase (ILK) in cancer progression

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Altered expression of syndecan-1 in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

MMP inhibition in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Akt-regulated pathways in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

The role of c-Jun and c-Fos expression in androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

The utility of tissue transglutaminase as a marker of apoptosis during treatment and progression of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0700

7 January 2021

Identifiers

DOI

10.1038/NCPURO0700

1 reference

15 August 2017

1 reference